Studies using stereotactic body radiotherapy (SBRT) for primary or centrally recurrent disease in the pelvis
| Study | Year of publication | Primary sites | Primary vs recurrent | Type of study | Patients included (n) | Notable outcomes |
| Albuquerque et al7 | 2019 | Cervix | Primary | Phase II prospective | 15 | The study closed early (with 15/21 patients having received treatment) due to poorer than expected outcomes. 2-year LC 70%; 2-year OS 53%. Grade 3 or higher late GI of 27% at 2 years |
| Haas et al48 | 2012 | Cervix | Primary | Retrospective | 5 | 1 year LC 100%. No grade 3 or higher toxicities |
| Hsieh et al49 | 2013 | Cervix | Primary | Retrospective | 9 | 2 grade 3 toxicities (thrombocytopenia and diarrhea). 3-year LC 77.8% |
| Ito et al6 | 2019 | Cervix | Primary | Phase I prospective | 6 | 22.5 Gy in three fractions determined to be tolerable fractionation with no dose-limiting toxicities |
| Kubicek et al50 | 2013 | Cervix (n=7), uterine (n=2), vaginal (n=2) | Primary | Retrospective | 11 | Median follow-up for surviving patients was 420 days. 8/11 patients alive at last follow-up, 1/11 with local recurrence. Two patients had acute toxicity (grade 2 dysuria and grade 2 GI); one patient with late toxicity (grade 3 GI bleed) |
| Lee et al4 | 2021 | Cervix | Primary | Retrospective | 25 | 3-year LC 80.9%, PFS 40.9%, OS 77.1%. Five (20%) grade 3 toxicity (3 genitourinary, 3 GI) |
| Marnitz et al51 | 2013 | Cervix | Primary | Prospective | 11 | Five grade 3 hematologic toxicities, one grade 4 toxicity (leukopenia). No local recurrence at median follow-up of 6 months |
| Kunos et al9 | 2009 | Cervix (n=1), uterine (n=1), ovarian (n=3) | Recurrence | Retrospective | 5 | Five case reports of locally recurrent gynecologic cancers treated with SBRT. No grade 3 toxicities reported |
BED, biologic effective dose; GI, gastrointestinal; LC, local control; OS, overall survival; PFS, progression-free survival; SBRT, stereotactic body radiotherapy.